Around 17,000 people are affected by myasthenia gravis in Germany. Many struggle to access appropriate care, face significant travel distances and endure long waiting times, which is particularly exhausting when muscle strength is already compromised.
To address these challenges, a team led by Charité physicians Dr Sophie Lehnerer,…
TransferAllianz e. V. is the German Association for Knowledge and Technology Transfer (KTT). The association promotes the transfer of knowledge between research institutions, businesses, and society. It's goal is to professionalize KTT in order to unlock the innovation potential of public research in Germany. To this end, TransferAllianz brings…
Contact
Rebecca Engels Project Manager GO-Bio initial T: +49 89 318814-38 engels@ascenion.de
The Life Science Digital Hub project is funded by the German Federal Ministry of Research, Technology and Space as part of the GO-Bio initial program.
Funding reference: 03LW0585.
Startup Pitch & Partner
BioVaria’s platform for entrepreneurs
BioVaria’s Startup Pitch & Partner programme offers a forum specifically for entrepreneurs, packed with valuable opportunities. Start-up projects in two different stages of maturity, ‘Emerging’ and ‘Rising’ present themselves to an interactive panel, the public and a jury of…
Promoting growth
Long-term partner for start-ups
We have already accompanied over 100 start-up projects. We usually acquire a minority share in the resulting companies.
We continue to support our portfolio companies on their growth trajectory and manage our shares as profitably as possible until exit – or, in the case of floatation or…
Building on the ASTP White Paper on enhancing spin-off processes in Europe, the report explores current support strategies at ASTP member institutions across different countries. It provides data-driven analysis of emerging challenges, strategic responses, and includes comprehensive policy recommendations. The data and insights aim to support…
HepaRegeniX plans to use the proceeds to complete its ongoing Phase Ib trial and to advance the Phase IIa clinical trial for HRX-215, the company’s lead clinical candidate in liver regeneration.
Prof. Dr. med. Lars Zender, the company’s co-founder, just gave the Karl Wilhelm von Kupffer Basic Science State-of-the-Art plenary talk at the 2025…
We have developed the Roadmap as part of our Life-Science Digital Hub project, funded by the German Federal Ministry of Education and Research as part of the GO-Bio initial programme (funding reference: 03LW0585).
The aim of the Roadmap is to provide researchers with clear guidelines for developing ideas towards application and…
An article by Dr Christian A. Stein, Dr Thomas Gazlig and Dr Jörn Erselius in published in Transfer & Innovation 1/2025, www.transfer-und-innovation.de, DUZ Verlags- und Medienhaus GmbH, Berlin Complete article (German only)
Organized by 11 leading technology transfer organizations, BioVaria serves as a vital bridge between cutting-edge academic research and commercial development, fostering partnerships across industry and academia. The 2025 event showcased 51 patent-protected technologies sourced from universities, research institutions, and university hospitals…
Mass spectrometry is a crucial tool in proteomics, generating vast amounts of data that are difficult to interpret due to their inherent complexity. DIA-NN 2.0 overcomes these challenges by leveraging artificial intelligence to filter noise, accurately identify proteins, and provide reliable quantification. It is the result of pioneering research…
This year’s focus was on the standard conditions for spin-offs that Ascenion has developed together with Charité, and the challenges of exploiting software-based inventions. Other fascinating topics included dealing with insolvent licensing partners and ‘the DNA’ of MTAs and CDAs. The participants contributed numerous case studies from their own…
Tuberculosis is the most common infectious disease worldwide. In 2023 alone, there were 10.6 million new tuberculosis infections and 1.3 million deaths from the disease. The long duration of treatment and the emergence of antibiotic resistance have led to increased investment and research activity in the tuberculosis area, including at the Leibniz…
